Early-stage cancer immunotherapy represents a promising yet underexplored frontier in cancer research. While immunotherapeutic strategies have achieved ...

Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically ...

Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and ...

The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...

Head and neck cancer (HNC) represents a significant global health challenge, characterized by aggressive local invasion, frequent recurrence, and poor survival rates. Beyond its physical burden, HNC ...

Over the past decade, the advent of immune checkpoint blockade (ICB) therapy has transformed cancer treatment. Unlike conventional cytotoxic and targeted therapies, immunotherapy leverages both the ...

Researchers at the Cancer Research Institute and the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have uncovered a critical mechanism that enables gastric cancer to spread to ...

Explore cancer drug resistance and its significant impact on treatment options and patient outcomes in modern cancer therapy.